TREATMENT AND DIAGNOSIS OF ABNORMAL BONE DENSITY WITH AN INHIBITOR OF THE GLYPICAN-SCLEROSTIN INTERACTION

摘要

Compositions and methods of treatment for abnormal bone density are disclosed based upon the finding that sclerostin must be bound to glypican in order to inhibit bone deposition. Methods for identifying agents that inhibit the glypican-sclerostin interaction are disclosed for treatment of bone deposition disorders. Diagnostic methods are also disclosed.